Paragon Therapeutics Strengthens Leadership Team
Paragon Therapeutics, a prominent biotechnology firm committed to leveraging the latest science and technology, has taken significant steps to enhance its executive team. Recent appointments include Mary Beth DeLena as Chief Legal Officer, Keri Lantz as Chief Financial Officer, and Hussam Shaheen as Chief Scientific Officer. This strategic reshuffling is designed to bolster the company’s strong commitment to developing advanced biologics to meet critical healthcare needs.
Key Appointments Open New Horizons
Mary Beth DeLena, who joins Paragon in a vital new role, brings over 25 years of legal expertise in the biotechnology sector. Her extensive background includes pivotal roles in corporate governance, compliance, and securities law, which are essential for shaping the future of Paragon’s operations. Prior to this role, she was General Counsel at PepGen and contributed significantly to the legal sectors of Alnylam Pharmaceuticals and Praecis Pharmaceuticals.
Keri Lantz's promotion to Chief Financial Officer is a testament to her vital role since joining Paragon. With a wealth of experience in finance, she has been instrumental in scaling business operations and developing financial frameworks that support the company's growth strategies. Her leadership has proven vital in establishing new entities and enhancing the company's financial ecosystem.
Scientific Leadership Unlocks Innovation
Dr. Hussam Shaheen’s promotion comes as a recognition of his remarkable contributions to Paragon’s scientific endeavors. Under his guidance, the company has successfully advanced a robust pipeline of development candidates, with many now undergoing clinical trials aimed at addressing pressing medical issues. His ability to foster collaboration and scientific rigor has been pivotal in establishing Paragon's identity in the biotech industry.
Strategic Vision for Future Growth
CEO Susanna High expressed her enthusiasm about the new leadership structure, highlighting the importance of these appointments in fostering innovation and continuing the company’s trajectory of success. The reshaping of the leadership team underscores Paragon Therapeutics’ commitment to expanding its influence in the biotechnology field and enhancing its capacity to deliver transformative therapies to patients.
About Paragon Therapeutics
Paragon Therapeutics, Inc. is a groundbreaking biotechnology company on a mission to revolutionize healthcare through the design of best-in-class complex biologics. Founded with a vision to address significant medical needs, Paragon is rapidly progressing its pipeline of innovative therapies into clinical applications. Established by Fairmount in 2021, the company’s headquarters is located in Waltham, Massachusetts. To learn more about its initiatives and developments, visit www.paragontherapeutics.com.
Frequently Asked Questions
What recent changes have been made in Paragon Therapeutics' leadership?
Mary Beth DeLena has been appointed as Chief Legal Officer, Keri Lantz promoted to Chief Financial Officer, and Hussam Shaheen is now the Chief Scientific Officer.
What is the role of Mary Beth DeLena at Paragon Therapeutics?
She serves as the Chief Legal Officer, bringing a wealth of experience in biotech law and corporate governance.
How has Keri Lantz contributed to Paragon Therapeutics?
Keri Lantz has played a crucial role in building the financial capacities essential for the company's growth since her arrival in 2023.
What achievements has Dr. Hussam Shaheen made?
Dr. Shaheen has successfully advanced over 18 development candidates, with 11 currently in clinical trials for major medical needs.
What is the overall vision of Paragon Therapeutics?
Paragon Therapeutics aims to create innovative therapies that address critical medical needs through cutting-edge science and technology.
